Researchers are actively exploring various strategies to enhance the GVT effect while minimizing the risk of GVHD. Some promising approaches include:
Selective depletion of alloreactive T-cells to reduce GVHD while preserving GVT activity. Use of donor lymphocyte infusions (DLI) to boost the GVT effect post-transplantation. Engineering of T-cells to specifically target tumor antigens. Modulation of the recipient's immune environment to favor anti-tumor responses.
